LISTEN to what Janet Woodcock says starting around the 25:30 mark of her interview on the 9th about MABs. Paraphrasing here, but she effectively said “we are not going to wait around for full data for MABs that look promising in the Severe/Critical phase of treatment as people are dying.” And the FDA already knows we are safe. They are starting our new trials in Phase II as a result. This is another tell, imo, that Leronlimab has an excellent chance of an EUA from our Phase III CD-12 trial.
News 
Market Data 
Discover 
